625 related articles for article (PubMed ID: 22755428)
1. A report of the epidemiology of de novo donor-specific anti-HLA antibodies (DSA) in "low-risk" renal transplant recipients.
Rebellato LM; Everly MJ; Haisch CE; Ozawa M; Briley KP; Parker K; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC
Clin Transpl; 2011; ():337-40. PubMed ID: 22755428
[TBL] [Abstract][Full Text] [Related]
2. Donor-specific anti-HLA antibody monitoring and removal in solid organ transplant recipients.
Everly MJ
Clin Transpl; 2011; ():319-25. PubMed ID: 22755425
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
Cooper JE; Gralla J; Chan L; Wiseman AC
Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
[TBL] [Abstract][Full Text] [Related]
4. De novo donor specific antibodies and patient outcomes in renal transplantation.
DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
[TBL] [Abstract][Full Text] [Related]
5. Long-term post transplant alloantibody monitoring: a single center experience.
Ntokou IS; Boletis JN; Apostolaki M; Vrani V; Zavos G; Kostakis A; Iniotaki A
Clin Transpl; 2011; ():341-50. PubMed ID: 22755429
[TBL] [Abstract][Full Text] [Related]
6. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience.
Leone JP; Bowers V; Baliga R; Sanders C; LeFor W; Becker D; Thompson D; Resto-Ruiz S; Lopez-Cepero M
Clin Transpl; 2011; ():373-9. PubMed ID: 22755434
[TBL] [Abstract][Full Text] [Related]
7. Targeted monitoring of donor-specific HLA antibodies following renal transplantation.
Almeshari K; Pall A; Chaballout A; Elgamal H; Almana H; Alzayer F; Abaalkhail N; Altalhi M
Clin Transpl; 2011; ():395-400. PubMed ID: 22755437
[TBL] [Abstract][Full Text] [Related]
8. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
Everly MJ; Rebellato LM; Haisch CE; Ozawa M; Parker K; Briley KP; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
Transplantation; 2013 Feb; 95(3):410-7. PubMed ID: 23380861
[TBL] [Abstract][Full Text] [Related]
9. Understanding the significance of low-level preformed donor-specific anti-HLA antibodies in renal transplant patients.
Wu P; Everly MJ; Jin J; Mao Y; Chen J
Clin Transpl; 2011; ():365-8. PubMed ID: 22755432
[TBL] [Abstract][Full Text] [Related]
10. A novel post-transplant alloantibody surveillance and intervention strategy that improves graft outcomes in sensitized renal transplant recipients.
Kimball PM; King A
Clin Transpl; 2011; ():369-72. PubMed ID: 22755433
[TBL] [Abstract][Full Text] [Related]
11. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
[TBL] [Abstract][Full Text] [Related]
12. Donor-specific HLA antibodies: risk factors and outcomes after kidney transplantation.
Kanter Berga J; Pallardo Mateu LM; Beltran Catalan S; Puig Alcaraz N; Sancho Calabuig A; Gavela Martinez E; Avila Bernabeu A; Crespo Albiach J
Transplant Proc; 2011; 43(6):2154-6. PubMed ID: 21839219
[TBL] [Abstract][Full Text] [Related]
13. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
[TBL] [Abstract][Full Text] [Related]
14. Summarizing the use of donor specific anti-HLA antibody monitoring in transplant patients.
Everly MJ
Clin Transpl; 2011; ():333-6. PubMed ID: 22755427
[TBL] [Abstract][Full Text] [Related]
15. Annual literature review of donor-specific HLA antibodies after organ transplantation.
Kaneku H
Clin Transpl; 2011; ():311-8. PubMed ID: 22755424
[TBL] [Abstract][Full Text] [Related]
16. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
Li X; Ishida H; Yamaguchi Y; Tanabe K
Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
[TBL] [Abstract][Full Text] [Related]
17. Effect of amino acid mismatch in the UNOS dataset.
Sasaki N; El-Awar N; Idica A
Clin Transpl; 2011; ():299-309. PubMed ID: 22755423
[TBL] [Abstract][Full Text] [Related]
18. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
[TBL] [Abstract][Full Text] [Related]
19. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
20. Successful transplantation across positive B-cell cross-match in deceased donor renal transplants.
Goh A; Oei E; Vathsala A
Transplant Proc; 2012 Jan; 44(1):193-9. PubMed ID: 22310613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
